By delivering rapamycin directly to cancer cells, Rapa-PLGA NPs effectively downregulated oncogenic genes including mTOR, HIF-α, BCL-2, and ABCC1, while simultaneously upregulating pro-apoptotic and stress response genes such as FOXO1 and MAPK. The gene discussed is MTOR; the disease is cancer.